Ablation of CaMKIIδ oxidation by CRISPR-Cas9 base editing as a therapy for cardiac disease is a research paper published in Science (2023). On theSindex it has a DataRank of 0. It has been cited 121 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
NHLBI NIH HHS
Grant: R01 HL130253
NHLBI NIH HHS
Grant: R01 HL157281
NICHD NIH HHS
Grant: P50 HD087351
National Institutes of Health
Grant: 5P50HD087351-07
Myoediting of Duchenne Muscular Dystrophy
National Institutes of Health
Grant: 5R01HL130253-06
Deciphering the role of a novel micropeptide in cardiac function and dysfunction
National Institutes of Health
Grant: 5R01HL157281-02
Transcriptional Control of Neonatal Heart Regeneration
FWCI
11.48
Citation Percentile
1.0%
Influential Citations
2
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals
Additional file 1 of Glucose fluctuations aggravate myocardial fibrosis via activating the CaMKII/Stat3 signaling in type 2 diabtetes
Additional file 1 of Glucose fluctuations aggravate myocardial fibrosis via activating the CaMKII/Stat3 signaling in type 2 diabtetes